Drugs / Daivobet
last change May 2024 re-read 2 minutes ago

Daivobet

also known as Daivobet ointment
Developed for
psoriasis · lichen planus · connective tissue disorder
Investigated by
LEO Pharma · Mansoura University

Trials 4 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01946386 Sep → Oct 2013 psoriasis LEO Pharma Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01607853 Jun → Oct 2012 psoriasis LEO Pharma Completed No outcome recorded
Phase 2 NCT00845481 Jan → Mar 2009 psoriasis LEO Pharma Completed No outcome recorded
Phase not applicable1 trial
NCT06327620 Jan 2022 → May 2024 lichen planus Mansoura University Unknown No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 23 trials
Phase 2 NCT02416258 Comparator Apr → Jun 2015 connective tissue disorder LEO Pharma Completed No outcome recorded
Phase 2 NCT01347255 Comparator May → Jun 2011 psoriasis LEO Pharma Completed No outcome recorded
Phase 2 NCT00875277 Comparator Apr → May 2009 psoriasis LEO Pharma Completed No outcome recorded
Phase 31 trial
Phase 3 NCT05919082 Comparator Jun 2023 → Feb 2024 psoriasis LEO Pharma Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Daivobet ClinicalTrials.gov intervention name — accepted as the source's own label NCT01607853
7

NCT00875277

NCT06327620

NCT01946386

NCT02416258

NCT00845481

NCT01347255

NCT05919082

Known as Daivobet ointment Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone.” NCT06327620
Route Topical “for Topical Use” NCT00845481